Tandem Diabetes Care (TNDM)
NASDAQ:TNDM
Want to see TNDM full AI Analyst Report?
TNDM Stock Chart & Stats
$20.61
-$0.45(-1.21%)
At close: 4:00 PM EST
$20.61
-$0.45(-1.21%)
Day’s Range― - ―
52-Week Range$9.98 - $29.65
Previous CloseN/A
Volume336.73K
Average Volume (3M)2.99M
Market Cap
$1.05B
Enterprise Value$1.61B
Total Cash (Recent Filing)$570.26M
Total Debt (Recent Filing)$734.74M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 05, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding68,529,090
10 Day Avg. Volume2,451,873
30 Day Avg. Volume2,994,857
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)9.53
Price to Sales (P/S)1.46
P/FCF Ratio-49.85
Enterprise Value/Market Cap1.54
Enterprise Value/Revenue1.57
Enterprise Value/Gross Profit2.85
Enterprise Value/Ebitda-22.40
Forecast
1Y Price Target
$31.64Price Target Upside53.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-0.69
Revenue Forecast (FY)$1.07B
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth & Margin ExpansionRapid top-line growth and materially higher gross margins expand Tandem’s installed base and recurring consumables revenue. Durable revenue momentum and improved unit economics support scale advantages, better absorption of fixed costs, and a clearer path to sustained profitability.
Improved Cash Position & FinancingA large cash balance plus convertible proceeds materially extend the company’s runway, funding international go‑direct expansion, product commercialization and supply-chain fixes. The financing reduces near‑term liquidity pressure and supports execution of multi‑quarter strategic initiatives.
Product & Regulatory MilestonesUnique regulatory clears and multiple platform integrations strengthen competitive differentiation and stickiness. A richer product roadmap (tubeless, closed‑loop pivotal) increases addressable market and recurring consumable demand, supporting durable installed‑base growth and longer customer lifetime value.
Bears Say
Elevated Leverage And Thin Equity CushionA much higher debt load and a reduced equity base weaken financial flexibility and increase vulnerability to operational shocks. If growth or margins slow, servicing or refinancing needs could force dilutive capital raises or constraint on strategic investments over multiple quarters.
Persistent Losses And Weak Free Cash FlowDespite margin improvement, ongoing operating and net losses with marginally negative FCF mean the business is not yet self‑sustaining. Continued investment needs and uneven cash conversion imply reliance on external funding until consistent positive FCF and net profitability are maintained.
Operational Execution RisksSupplier capacity constraints and friction from the pharmacy PayGo rollout threaten recurring consumable sales and customer experience. These execution issues can depress reorder rates, slow pharmacy channel conversion, and impair long‑term retention and revenue predictability across quarters.
Tandem Diabetes Care News
TNDM FAQ
What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest stock price was $9.98 and its highest was $29.65 in the past 12 months.
What is Tandem Diabetes Care’s market cap?
Tandem Diabetes Care’s market cap is $1.05B.
When is Tandem Diabetes Care’s upcoming earnings report date?
Tandem Diabetes Care’s upcoming earnings report date is Aug 05, 2026 which is in 47 days.
How were Tandem Diabetes Care’s earnings last quarter?
Tandem Diabetes Care released its earnings results on May 07, 2026. The company reported -$0.298 earnings per share for the quarter, beating the consensus estimate of -$0.444 by $0.146.
Is Tandem Diabetes Care overvalued?
According to Wall Street analysts Tandem Diabetes Care’s price is currently Undervalued.
Does Tandem Diabetes Care pay dividends?
Tandem Diabetes Care does not currently pay dividends.
What is Tandem Diabetes Care’s EPS estimate?
Tandem Diabetes Care’s EPS estimate is -0.33.
How many shares outstanding does Tandem Diabetes Care have?
Tandem Diabetes Care has 68,529,090 shares outstanding.
What happened to Tandem Diabetes Care’s price movement after its last earnings report?
Tandem Diabetes Care reported an EPS of -$0.298 in its last earnings report, beating expectations of -$0.444. Following the earnings report the stock price went down -16.188%.
Which hedge fund is a major shareholder of Tandem Diabetes Care?
Currently, no hedge funds are holding shares in TNDM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tandem Diabetes Care Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.64 (53.53% Upside)
$31.64 (53.53% Upside)
Blogger Sentiment
Bullish
TNDM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 704.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.26%
12-Months-Change
Fundamentals
Return on Equity
-68.29%
Trailing 12-Months
Asset Growth
25.08%
Trailing 12-Months
Company Description
Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
TNDM Company Deck
TNDM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong operational and financial momentum—record shipments and sales, meaningful margin expansion, positive cash generation, a strengthened balance sheet, international go‑direct progress, and multiple product and integration milestones (Android Mobi, pregnancy clearance, FreeStyle Libre 3+ and G7 compatibility, Mobi Tubeless filing). Management acknowledged manageable near‑term headwinds from infusion set supplier shortages and the early operational friction of the PayGo pharmacy transition, plus some international timing and one‑time effects. Overall, the positive results, clear roadmap for product launches, and reaffirmed FY guidance outweigh the disclosed challenges.View all TNDM earnings summariesTNDM Revenue Breakdown
74.21% U.S.
25.79% International
TNDM Stock 12 Month Forecast
Average Price Target
$31.64
▲(53.53% Upside)
Technical Analysis
Ownership Overview
0.99% Insiders
21.41% Mutual Funds
42.26% Other Institutional Investors
10.46% Public Companies and
Individual Investors